ALEC

Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegenerative diseases. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its clinical programs include AL001 (latozinemab), AL101, and AL002. In addition, the Company also focuses on preclinical and research programs in its pipeline for indications, including Alzheimer’s disease, Parkinson’s disease, and oncology. Its first product candidate, latozinemab, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients.